Drug intelligence / Profile preview

triamcinolone acetonide (Apotex)

Development stage: Unknown
Lead developer: Apotex
Modality: Small Molecules
Administration: Intranasal

Overview

Triamcinolone acetonide is a synthetic corticosteroid small molecule developed by Apotex as a generic bioequivalent to the reference drug Nasacort AQ. It is administered as an aqueous nasal spray for the treatment of seasonal and perennial allergic rhinitis. The drug functions as a glucocorticoid receptor agonist, exerting potent anti-inflammatory and immunosuppressive effects by inhibiting the release of inflammatory mediators such as cytokines, histamines, and leukotrienes. This localized action in the nasal mucosa effectively alleviates symptoms including sneezing, rhinorrhea, and nasal congestion.

Other names: triamcinolone acetonide aqueous nasal spray (Apotex Inc.)

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on triamcinolone acetonide (Apotex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on triamcinolone acetonide (Apotex).

Explore the full profile